# China NMPA Product Recall - Disposable connecting tube

Source: https://www.globalkeysolutions.net/records/china_product_recall/guangzhou-runhong-pharmaceutical-technology-co-ltd/247a94e1-9af0-4c25-8bb1-d5d7cc6e68d8/
Source feed: China

> China NMPA product recall for Disposable connecting tube by Guangzhou Runhong Pharmaceutical Technology Co., Ltd. published April 06, 2022. Recall level: Level 3 Recall. Yangzhou Yangsheng Pharmaceutical Technology Co., Ltd. initiated a voluntary Level III recall for it

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Yangzhou Yangsheng Pharmaceutical Technology Co., Ltd. voluntarily recalls disposable connecting tubes.
- Company Name: Guangzhou Runhong Pharmaceutical Technology Co., Ltd.
- Publication Date: 2022-04-06
- Product Name: Disposable connecting tube
- Recall Level: Level 3 Recall
- Recall Reason: Upon receiving adverse event reports from medical institutions, it was found that the three-way valves with disposable connecting tubes may experience loose connections during use, some products may leak, and some products may pose a risk of harm to the human body.
- Discovering Company: Yangzhou Yangsheng Pharmaceutical Technology Co., Ltd.
- Manufacturing Company: Guangzhou Runhong Pharmaceutical Technology Co., Ltd.
- Summary: Yangzhou Yangsheng Pharmaceutical Technology Co., Ltd. initiated a voluntary Level III recall for its Disposable Connecting Tubes, as announced by the National Medical Products Administration (NMPA) and the Jiangsu Provincial Drug Administration on April 6, 2022. The recall was prompted by adverse event reports from medical institutions, highlighting a critical product flaw: the three-way valve of the connecting tube may develop loose connections during use, potentially causing leakage. This defect presents a risk of harm to patients, especially when the devices are used as extension connections in operating rooms and intensive care units. The affected products, distributed within China, include batches 20200821 (3,000 units), 20210505 (6,000 units), and 20210805 (6,000 units), totaling 15,000 units. To address this, the company is actively communicating with distributors and hospitals to gather information on adverse events, diligently following up with customers, compiling comprehensive statistics on affected batch numbers, and ensuring all relevant stock is promptly identified and recalled. These actions are crucial for mitigating further risks and upholding product safety under NMPA's regulatory guidance.

Company: https://www.globalkeysolutions.net/companies/guangzhou-runhong-pharmaceutical-technology-co-ltd/ce0b2e2d-a3da-4ef5-b05d-376bb95a7622/